Novavax (NASDAQ:NVAX) Trading Up 5.4% – What’s Next?

Posted by Geri Gentry on Jun 23rd, 2026

Novavax, Inc. (NASDAQ:NVAX – Get Free Report) was up 5.4% on Tuesday . The company traded as high as $9.43 and last traded at $9.4860. Approximately 622,763 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 4,929,272 shares. The stock had previously closed at $9.00.

Wall Street Analyst Weigh In

NVAX has been the subject of several recent analyst reports. B. Riley Financial reaffirmed a “buy” rating on shares of Novavax in a report on Thursday, April 9th. HC Wainwright upped their price objective on Novavax from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, February 27th. TD Cowen raised their target price on Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Weiss Ratings downgraded shares of Novavax from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research report on Sunday, May 31st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $13.00.

View Our Latest Analysis on Novavax

Novavax Trading Up 2.3%

The firm has a fifty day moving average of $9.10 and a two-hundred day moving average of $8.66. The company has a market cap of $1.51 billion, a PE ratio of -15.92 and a beta of 2.45.

Novavax (NASDAQ:NVAX – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.19. The business had revenue of $118.90 million for the quarter, compared to the consensus estimate of $79.81 million. Novavax had a negative net margin of 14.73% and a negative return on equity of 14.82%. The company’s revenue was down 79.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.93 earnings per share. Sell-side analysts expect that Novavax, Inc. will post -0.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Flagship Harbor Advisors LLC bought a new stake in Novavax during the 4th quarter valued at $33,000. Quarry LP bought a new position in shares of Novavax in the third quarter worth $33,000. Duncker Streett & Co. Inc. boosted its holdings in shares of Novavax by 917.3% in the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,825 shares during the period. KBC Group NV grew its position in shares of Novavax by 34.9% in the first quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 1,229 shares in the last quarter. Finally, State of Wyoming purchased a new position in shares of Novavax in the second quarter valued at $52,000. 53.04% of the stock is owned by institutional investors.

Novavax Company Profile

(Get Free Report)

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.